クキュルビタシンBによるSTING依存DNA損傷経路の誘導は,骨肉腫における免疫療法の有効性を高めます
Bin Luo1, Qing Lu2, Qiang Wang1
1Department of Orthopaedics, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu 215500, China.
Iranian journal of basic medical sciences
|September 2, 2025
まとめ
クキュルビタシンB (CuB) は,がんDNAを損傷し,免疫反応を活性化することで,骨肉腫に対する有望な効果を示しています. CuBを抗PD- L1療法と併用すると,腫瘍抑制効果がさらに強化されます.
科学分野:
- 腫瘍学
- 免疫学
- 自然製品 化学
背景:
- 骨肉腫 (OS) は,治療の選択肢が限られている攻撃的な骨癌です.
- キュルビタシンB (CuB) は天然の化合物で,抗腫瘍性がありますが,OSにおけるその役割は完全に理解されていません.
研究 の 目的:
- クキュルビタシンB (CuB) の抗腫瘍効果を骨肉腫 (OS) で調査する.
- OSにおけるCuBの作用の基礎となる分子メカニズムを探求する.
- CuBと抗プログラム死亡リガンド1 (PD- L1) 治療のシナジスティックの可能性を評価する.
主な方法:
- 細胞活性,増殖,アポトーシス,および細胞サイクルアッセイは,CuBで治療されたOS細胞で行われました.
- DNAの損傷,STING経路の活性化,免疫細胞の浸透を分析した.
- 腫瘍の成長と治療効果を評価するために,in vivoの異種移植モデルを使用した.
主要な成果:
- CuBはOS細胞の増殖を抑制し,アポトーシスを誘発し,G2/M細胞サイクル停止を引き起こしました.
- CuBはSTING経路を活性化し,DNA損傷を引き起こし,腫瘍の成長と転移を in vivoで減少させた.
- CuBはCD8+とCD4+のT細胞の浸透を促進し,同時にT細胞の調節と骨髄系由来抑制細胞を減少させた.
- 抗PD- L1との併用療法により,腫瘍の成長が著しく抑制されました.
結論:
- クキュルビタシンBは,DNAダメージ誘導とSTING経路の活性化により,重要な抗骨肉腫活性を示しています.
- CuBは抗腫瘍免疫反応を強化し,免疫療法剤としての可能性を示唆しています.
- CuBは抗PD- L1療法と連携し,骨髄腫治療の有望な組み合わせ戦略を提供します.
関連する概念動画
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K


